Tuesday August 14, 2018 15:35

Heathcare Press Release : 21 May 2018

Head-to-Head Trial Shows Refixia(R) Achieves Greater Total Factor IX Exposure in People With Heathcare—21 May 18

Adults with haemophilia B who received a single dose Refixia(R) (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those treated with rFIXFc (recombinant factor IX-Fc fusion protein). The head-to-head paradigm7 trial also observed

NovoEight(R) Maintains Potency When Stored at 40?C Offering People With Haemophilia A Increased Heathcare—21 May 18

A new long term stability study has shown that haemophilia A treatment NovoEight(R) (turoctocog alfa) remains potent after three months exposure to temperatures of 40ºC.[1] The results were presented today at the WFH 2018 World Congress in Glasgow,